Form 4: Bone Biologics CEO Jeff Frelick Reports Stock Option Grant and Holdings
SEC Form 4 Filing
Bone Biologics CEO Jeff Frelick reports the acquisition of 54,110 stock options and existing holdings.
Summary
- Jeff Frelick, CEO of Bone Biologics Corp, filed a Form 4 detailing changes in his beneficial ownership of company securities.
- The report indicates the acquisition of 54,110 employee stock options with an exercise price of $0.9678 on January 15, 2025.
- These options vest immediately and expire on January 15, 2027.
- The report also lists existing holdings of employee stock options with various exercise prices and vesting dates.
- Mr. Frelick directly owns 2,151 shares of common stock.
Sentiment
Score: 6
Explanation: The document is a routine filing and does not contain any information that would be considered significantly positive or negative. It is a neutral event.
Positives
- The grant of stock options to the CEO aligns his interests with those of shareholders.
- The immediate vesting of the newly granted options could incentivize the CEO to drive short-term performance.
Risks
- The exercise of a large number of options could potentially dilute existing shareholders' equity.
Industry Context
This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the holdings of key executives.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotechnology sector.
- The vesting schedules and exercise prices are typical for such grants, often designed to align executive interests with long-term shareholder value.
- Companies like Amgen, Regeneron, and Biogen also use stock options as part of their executive compensation packages.
Stakeholder Impact
- The stock option grant could be viewed positively by shareholders as it aligns management's interests with the company's performance.
- The potential dilution from the exercise of options is a consideration for shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/15/2025 | Date of the earliest transaction reported, which includes the grant of 54,110 stock options and the vesting date of those options. |
| 01/15/2027 | Expiration date of the 54,110 stock options granted on January 15, 2025. |
| 01/17/2025 | Date of the report filing and the date of the signature of the reporting person. |
| 01/17/2026 | Vesting date of 25,000 employee stock options with an exercise price of $3.61. |
| 12/27/2025 | Vesting date of 173 employee stock options with an exercise price of $9,540. |
| 05/26/2026 | Vesting date of 44 employee stock options with an exercise price of $12,300. |
| 01/25/2025 | Vesting date of 157 employee stock options with an exercise price of $57.6. |
Keywords
stock options, Form 4, beneficial ownership, equity incentive plan, CEO, Bone Biologics, BBLG
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.